Table 3.
Prognostic Models in Follicular Lymphoma and Correlation with POD24
| Study | N | Accuracy | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|---|---|
| Jurinovic18 |
GLSG (N=132)/ BCCA (N=102) |
FLIPI | 67%/64% | 78%/70% | 56%/58% | 27%/33% | 92%/87% |
| m7-FLIPI | 70%/65% | 61%/43% | 79%/86% | 38%/48% | 91%/84% | ||
| POD24-PI | 73%/67% | 78%/61% | 67%/73% | 33%/40% | 94%/87% | ||
| Huet77 | N = 488 | 23-gene predictor | - | 43% | 79% | 38% | 82% |
| Mir75 | N = 1202 | FLEX | - | 60% | 68% | - | - |
| FLIPI | - | 53% | 58% | - | - | ||
| FLIPI-2 | - | 53% | 59% | - | - | ||
| PRIMA-PI | - | 69% | 48% | - | - | ||
| Kuroki19 | N = 45 | High TLG and non-CR/CMR | 89% | 56% | 100% | 100% | 87% |
| Hu89 | N = 135 | PRIMA-PI | 54% | 75% | 50% | ||
| PRIMA-PIC | 56% | 92% | 48% | ||||
| Bachy16 | N = 1135 | Low-risk | interm-risk | high-risk | P | ||
| FLIPI | 16% | 21% | 31% | 1.36*10− 5 | - | ||
| PRIMA-PI | 14% | 21% | 38% | 1.41*10− 12 | - | ||
| Tobin93 | Low PD-L2 | highPD-L2 | P | ||||
| discovery cohort(N = 198) | PD-L2 | 45.70% | 16.30% | 0 .001 | |||
| GLSG2000(N = 138) | 54.2% | 14.30% | 0.011 | ||||
| BCCA(N = 45) | 46.70% | 24.00% | 0.011 | ||||
PPV positive predictive value, NPV negative predictive value, FLIPI follicular lymphoma international prognostic index, POD24-PI progression of disease within 24 months prognostic index, FLEX follicular Lymphoma Evaluation Index PRIMA-PI PRIMA-Prognostic Index TLG total lesion glycolysis, non-CR/CMR less than complete [metabolic] response